PE20170248A1 - El control efectivo y eficaz del fosfato serico para una osificacion optima - Google Patents

El control efectivo y eficaz del fosfato serico para una osificacion optima

Info

Publication number
PE20170248A1
PE20170248A1 PE2016002698A PE2016002698A PE20170248A1 PE 20170248 A1 PE20170248 A1 PE 20170248A1 PE 2016002698 A PE2016002698 A PE 2016002698A PE 2016002698 A PE2016002698 A PE 2016002698A PE 20170248 A1 PE20170248 A1 PE 20170248A1
Authority
PE
Peru
Prior art keywords
fgf23
seq
ligand
effective
seric
Prior art date
Application number
PE2016002698A
Other languages
English (en)
Spanish (es)
Inventor
Emil Kakkis
Tomohiro Sudo
Martin Javier San
Original Assignee
Ultragenyx Pharmaceutical Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc, Kyowa Hakko Kirin Co Ltd filed Critical Ultragenyx Pharmaceutical Inc
Publication of PE20170248A1 publication Critical patent/PE20170248A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PE2016002698A 2014-06-09 2015-05-29 El control efectivo y eficaz del fosfato serico para una osificacion optima PE20170248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09

Publications (1)

Publication Number Publication Date
PE20170248A1 true PE20170248A1 (es) 2017-04-14

Family

ID=54769049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002698A PE20170248A1 (es) 2014-06-09 2015-05-29 El control efectivo y eficaz del fosfato serico para una osificacion optima

Country Status (25)

Country Link
US (5) US10639360B2 (https=)
EP (3) EP3845245B1 (https=)
JP (2) JP6808493B2 (https=)
KR (4) KR102947335B1 (https=)
CN (1) CN106604743A (https=)
AR (2) AR100689A1 (https=)
AU (1) AU2015275128C1 (https=)
BR (2) BR112016028567A2 (https=)
CA (1) CA2949234C (https=)
CL (1) CL2016003179A1 (https=)
CY (1) CY1124328T1 (https=)
DK (2) DK3151859T3 (https=)
ES (2) ES3040805T3 (https=)
FI (1) FI3845245T3 (https=)
HR (2) HRP20210250T1 (https=)
HU (2) HUE053271T2 (https=)
LT (2) LT3845245T (https=)
MX (2) MX381052B (https=)
PE (1) PE20170248A1 (https=)
PL (2) PL3845245T3 (https=)
PT (2) PT3845245T (https=)
RS (2) RS61443B1 (https=)
SI (2) SI3151859T1 (https=)
SM (2) SMT202500342T1 (https=)
WO (1) WO2015191312A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
BR112021019337A2 (pt) * 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
EP4676955A2 (en) * 2023-03-10 2026-01-14 Ultragenyx Pharmaceutical Inc. Human fgf23-binding antibodies with improved affinity and efficacy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (en) 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4527982B2 (ja) * 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
EP1833848A2 (en) * 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.

Also Published As

Publication number Publication date
CA2949234A1 (en) 2015-12-17
MX2021003740A (es) 2021-05-27
ES3040805T3 (en) 2025-11-05
JP2017524656A (ja) 2017-08-31
RS61443B1 (sr) 2021-03-31
SI3845245T1 (sl) 2025-10-30
PL3845245T3 (pl) 2025-12-22
LT3845245T (lt) 2025-09-25
EP3151859B1 (en) 2020-11-25
WO2015191312A1 (en) 2015-12-17
KR102947335B1 (ko) 2026-04-03
PT3845245T (pt) 2025-09-16
AR100689A1 (es) 2016-10-26
US10639360B2 (en) 2020-05-05
BR112016028567A2 (pt) 2018-01-30
KR20170013993A (ko) 2017-02-07
US20260035449A1 (en) 2026-02-05
EP3845245A1 (en) 2021-07-07
HRP20251099T1 (hr) 2025-11-07
JP2021050226A (ja) 2021-04-01
SI3151859T1 (sl) 2021-06-30
PT3151859T (pt) 2021-02-03
US20200330575A1 (en) 2020-10-22
SMT202500342T1 (it) 2025-11-10
ES2851674T3 (es) 2021-09-08
KR20210099180A (ko) 2021-08-11
US11771748B2 (en) 2023-10-03
CN106604743A (zh) 2017-04-26
KR20260051107A (ko) 2026-04-15
HUE073105T2 (hu) 2025-12-28
LT3151859T (lt) 2021-03-25
JP6993490B2 (ja) 2022-02-03
SMT202100096T1 (it) 2021-03-15
EP4647444A3 (en) 2026-01-21
US12358976B2 (en) 2025-07-15
US20220133871A1 (en) 2022-05-05
MX2016016296A (es) 2017-10-12
EP3151859A4 (en) 2018-01-17
KR20240093956A (ko) 2024-06-24
EP3845245B1 (en) 2025-06-25
HRP20210250T1 (hr) 2021-04-02
CA2949234C (en) 2022-03-22
US20240115683A1 (en) 2024-04-11
DK3151859T3 (da) 2021-02-15
US20150353633A1 (en) 2015-12-10
EP3151859A1 (en) 2017-04-12
EP4647444A2 (en) 2025-11-12
CL2016003179A1 (es) 2017-11-03
HUE053271T2 (hu) 2021-06-28
AU2015275128A1 (en) 2016-12-08
BR122023023102A2 (pt) 2024-03-05
JP6808493B2 (ja) 2021-01-06
FI3845245T3 (fi) 2025-09-09
AR131056A2 (es) 2025-02-12
RS67294B1 (sr) 2025-11-28
PL3151859T3 (pl) 2021-07-26
DK3845245T3 (da) 2025-09-15
AU2015275128C1 (en) 2020-02-13
AU2015275128B2 (en) 2019-10-31
US11202822B2 (en) 2021-12-21
MX381052B (es) 2025-03-12
CY1124328T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
PE20170248A1 (es) El control efectivo y eficaz del fosfato serico para una osificacion optima
Gan Exponential synchronization of stochastic Cohen–Grossberg neural networks with mixed time-varying delays and reaction–diffusion via periodically intermittent control
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
Grahovac et al. Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion
MX375446B (es) Moduladores de receptor de hormona de crecimiento.
EA201492116A1 (ru) Композиции и способы для модулирования экспрессии mecp2
EA201001135A1 (ru) Интратекальное лечение невропатической боли агонистами ar
EA201492122A1 (ru) Композиции и способы для модулирования экспрессии utrn
MX2017008218A (es) Anticuerpos anti-csf1r para tratar pvns.
JOP20190175A1 (ar) مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
MX2022011281A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
CU20190067A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
EA201591395A1 (ru) Ряд испарителей для системы очистки воды
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis
EA201691413A1 (ru) Селективные антагонисты nr2b
MX2017000306A (es) Metodos para tratar hipotension.
MX342322B (es) Compuestos organicos.
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
Mandych et al. Possibility of using network plans for solving ecological problems of water supply systems reconstruction